BAR1 LIFE Stock Australian S.E.

BD1

Pharmaceuticals

End-of-day quote Australian S.E.			5-day change	1st Jan Change
- ^AUD	-.--%		-.--%	-

10-23	Inoviq CEO to Step Down	MT
08-27	INOVIQ Ltd Reports Earnings Results for the Full Year Ended June 30, 2026	CI

INOVIQ Ltd is an Australia-based biotechnology company developing diagnostics and therapeutics for cancer. The Company's commercialized products include EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The Company is also advancing clinical-stage diagnostics for the detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumors.

Employees

Sector

Pharmaceuticals

More about the company

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.1375AUD

Average target price

0.7000AUD

Spread / Average Target

+409.09%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - BAR1 LIFE

Revisions to estimates

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - BAR1 LIFE

Company calendar

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	19.36M 13.63M 12.23M 11.3M 10.24M 19.13M 1.3B 135M 53.83M 679M 51.14M 50.06M 2.16B	P/E 2027 *	-3.44x	P/E 2028 *	13.8x
Enterprise Value	19.36M 13.63M 12.23M 11.3M 10.24M 19.13M 1.3B 135M 53.83M 679M 51.14M 50.06M 2.16B	EV / Sales 2027 *	13.8x	EV / Sales 2028 *	1.76x
Free-Float	66.05%	Yield 2027 *	-	Yield 2028 *	-

10-23	Inoviq CEO to Step Down	MT
08-27	INOVIQ Ltd Reports Earnings Results for the Full Year Ended June 30, 2026	CI
08-26	INOVIQ Ltd Auditor Raises 'Going Concern' Doubt	CI
06-25	Inoviq Says CAR-Exosome Platform Showed In Vitro Tumor-Killing Activity in Ovarian Cancer; Shares Down 4%	MT
02-18	INOVIQ Ltd Reports Earnings Results for the Half Year Ended December 31, 2025	CI
12-23	INOVIQ Appoints Chief Scientific Officer	MT
12-23	INOVIQ Limited Announces Management Changes, Effective January 12, 2026	CI
12-18	Inoviq says Peter Gunzburg elected to role of chairman	RE
11-27	Inoviq Ltd Elects Peter Gunzburg as Non-Executive Director	CI
11-27	Inoviq says chairman David Williams to step down at year-end	RE
17/10/25	INOVIQ Ltd Announces Appointment of Peter Gunzburg as A Non-Executive Director, Effective 20 October 2025	CI
13/10/25	Inoviq completes A$9.5 million placement	RE
09/10/25	Inoviq Ltd seeks trading halt	RE

07/07/23	INOVIQ AND PROMEGA ANNOUNCE GLOBAL JOINT MARKETING AGREEMENT FOR EXO-NET EXOSOME ISOLATION AND NUCLEIC ACID PURIFICATION SOLUTIONS	AQ
27/07/22	INOVIQ : IIQ Appendix 4C & Quarterly Activities Report - June 2022	PU
29/04/22	INOVIQ : IIQ Appendix 4C & Quarterly Activities Report - March 2022	PU
06/04/22	INOVIQ : Updated Investor Presentation	PU
07/12/21	BARD1 Life Sciences : Application for quotation of securities - BD1	PU

Manager	Title	Age	Since
Mark Edwards DFI	Director of Finance/CFO	-	02/11/2022
Rebecca Lim CTO	Chief Tech/Sci/R&D Officer	-	12/01/2026
Emma Ball PRN	Corporate Officer/Principal	-	22/04/2025

Director	Title	Age	Since
Philip Powell BRD	Director/Board Member	67	18/06/2019
Robert Johnston BRD	Director/Board Member	-	18/06/2019
Geoff Cumming CHM	Chairman	-	28/07/2020

BAR1 LIFE Stock Australian S.E.

Stocks

BD1

Pharmaceuticals

Valuation: BAR1 LIFE

Latest news: BAR1 LIFE

Press Releases: BAR1 LIFE

Managers and Directors: BAR1 LIFE

Other Pharmaceuticals

Financials

Company Profile

Analysts' Consensus

Annual profits - Rate of surprise

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BAR1 LIFE	-.--%	-.--%	-	-	13.63M
ELI LILLY AND COMPANY	+0.50%	+1.38%	+57.09%	+129.96%	1,148B
JOHNSON & JOHNSON	+0.86%	+5.14%	+45.00%	+86.15%	652B
ABBVIE INC.	-0.14%	+0.42%	+25.69%	+105.85%	505B
ROCHE HOLDING AG	+0.51%	+2.22%	+53.92%	+66.10%	384B
MERCK & CO., INC.	-0.63%	-5.97%	+61.93%	+37.06%	348B
NOVARTIS AG	+2.98%	+3.00%	+34.76%	+56.85%	294B
ASTRAZENECA PLC	+1.18%	-0.64%	+2.68%	+26.22%	264B
AMGEN INC.	+0.87%	+3.08%	+54.69%	+72.74%	244B
GILEAD SCIENCES, INC.	+0.08%	+3.67%	+35.05%	+107.78%	197B
Average	+1.11%	+1.39%	+41.20%	+76.52%	448.57B
Weighted average by Cap.	+1.32%	+1.50%	+44.92%	+89.14%

	2027 *	2028 *
Net sales	1.4M 986K 884K 818K 740K 1.38M 93.87M 9.77M 3.89M 49.12M 3.7M 3.62M 156M	11M 7.74M 6.95M 6.42M 5.82M 10.87M 738M 76.8M 30.59M 386M 29.06M 28.45M 1.23B
Net income	-	-
Net Debt	-	-